BRPI0609020A2 - polipeptídeo, proteína de fusão, molécula de ácido nucleido purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptídeo, composição farmacêutica, composição de vacina, métodos para monitorar o tratamento terapêutico de doença em paciente e para a identificação de um composto que é eficaz no tratamento e/ou diagnóstico de doença, kit, animal não humano transgênico ou knockout, método para a triagem quanto a um composto eficaz para tratar doença, e, método para selecionar compostos biologicamente ativos" - Google Patents
polipeptídeo, proteína de fusão, molécula de ácido nucleido purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptídeo, composição farmacêutica, composição de vacina, métodos para monitorar o tratamento terapêutico de doença em paciente e para a identificação de um composto que é eficaz no tratamento e/ou diagnóstico de doença, kit, animal não humano transgênico ou knockout, método para a triagem quanto a um composto eficaz para tratar doença, e, método para selecionar compostos biologicamente ativos"Info
- Publication number
- BRPI0609020A2 BRPI0609020A2 BRPI0609020A BRPI0609020A BRPI0609020A2 BR PI0609020 A2 BRPI0609020 A2 BR PI0609020A2 BR PI0609020 A BRPI0609020 A BR PI0609020A BR PI0609020 A BRPI0609020 A BR PI0609020A BR PI0609020 A2 BRPI0609020 A2 BR PI0609020A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- compound
- polypeptide
- patient
- effective
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 4
- 201000010099 disease Diseases 0.000 title 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 4
- 238000000034 method Methods 0.000 title 4
- 229920001184 polypeptide Polymers 0.000 title 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 239000002253 acid Substances 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000009261 transgenic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0504767.5A GB0504767D0 (en) | 2005-03-08 | 2005-03-08 | Lipocalin protein |
| PCT/GB2006/000820 WO2006095164A1 (en) | 2005-03-08 | 2006-03-08 | Lipocalin protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0609020A2 true BRPI0609020A2 (pt) | 2016-11-29 |
Family
ID=34452020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0609020A BRPI0609020A2 (pt) | 2005-03-08 | 2006-03-08 | polipeptídeo, proteína de fusão, molécula de ácido nucleido purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptídeo, composição farmacêutica, composição de vacina, métodos para monitorar o tratamento terapêutico de doença em paciente e para a identificação de um composto que é eficaz no tratamento e/ou diagnóstico de doença, kit, animal não humano transgênico ou knockout, método para a triagem quanto a um composto eficaz para tratar doença, e, método para selecionar compostos biologicamente ativos" |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080254035A1 (enExample) |
| EP (1) | EP1869074A1 (enExample) |
| JP (1) | JP4933527B2 (enExample) |
| KR (1) | KR20070118614A (enExample) |
| CN (1) | CN101189257A (enExample) |
| AU (1) | AU2006221859B2 (enExample) |
| BR (1) | BRPI0609020A2 (enExample) |
| CA (1) | CA2599540A1 (enExample) |
| EA (1) | EA011816B1 (enExample) |
| GB (1) | GB0504767D0 (enExample) |
| IL (1) | IL185547A0 (enExample) |
| MX (1) | MX2007010809A (enExample) |
| NO (1) | NO20075068L (enExample) |
| UA (1) | UA94221C2 (enExample) |
| WO (1) | WO2006095164A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006020710D1 (de) | 2005-04-22 | 2011-04-28 | Fred Hutchinson Cancer Res Foundation | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| AU2008287426B2 (en) | 2007-08-10 | 2014-06-26 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| CA2724384A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
| EP3281955A1 (en) | 2008-10-02 | 2018-02-14 | Aptevo Research and Development LLC | Cd86 antagonist multi-target binding proteins |
| EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| HRP20171291T1 (hr) | 2010-02-04 | 2017-10-20 | Morphotek, Inc. | Polipeptidi i konjugati klorotoksina i njihove uporabe |
| CN103097403B (zh) | 2010-05-11 | 2017-04-19 | 弗雷德哈钦森癌症研究中心 | 氯毒素变体、缀合物及其使用方法 |
| CN103154023B (zh) * | 2010-08-16 | 2017-04-05 | 皮里斯制药有限公司 | 铁调素的结合蛋白 |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| KR20150004856A (ko) | 2012-04-20 | 2015-01-13 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | Cd3 결합 폴리펩타이드 |
| CA2913127A1 (en) * | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Methods for screening |
| JP6392315B2 (ja) | 2013-03-14 | 2018-09-19 | イミュソフト コーポレーション | インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法 |
| EP3027204B1 (en) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| AU2014342020C1 (en) | 2013-10-31 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof |
| WO2015095553A1 (en) * | 2013-12-20 | 2015-06-25 | Nephrogenesis, Llc | Methods and apparatus for kidney dialysis |
| AU2014368892B2 (en) | 2013-12-20 | 2019-06-13 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| JP5866053B1 (ja) * | 2014-12-15 | 2016-02-17 | 株式会社ファンケル | 皮膚粘弾性のマーカー及びその利用 |
| EP4177336A1 (en) | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| JP6985934B2 (ja) | 2015-04-29 | 2021-12-22 | フレッド ハッチンソン キャンサー リサーチ センター | 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 |
| WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| KR102784293B1 (ko) | 2015-09-21 | 2025-03-20 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| CN109121413A (zh) | 2016-04-14 | 2019-01-01 | 弗莱德哈钦森癌症研究中心 | 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法 |
| CA3021011A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| MX2019010812A (es) | 2017-03-17 | 2019-12-11 | Hutchinson Fred Cancer Res | Proteinas de fusion inmunomoduladoras y sus usos. |
| CN111565737A (zh) | 2017-12-14 | 2020-08-21 | 蓝鸟生物公司 | Daric白细胞介素受体 |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
| US12398402B2 (en) | 2018-09-12 | 2025-08-26 | Fred Hutchinson Cancer Center | Reducing CD33 expression to selectively protect therapeutic cells |
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| EP3895052A4 (en) | 2018-12-14 | 2022-10-26 | 2seventy bio, Inc. | DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| CA3138972A1 (en) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Clec12a-binding polypeptides and uses thereof |
| SG11202111927QA (en) | 2019-05-08 | 2021-11-29 | 2Seventy Bio Inc | Cll-1 targeted immunotherapies |
| JP2022539248A (ja) | 2019-07-02 | 2022-09-07 | フレッド ハッチンソン キャンサー リサーチ センター | 組換えａｄ３５ベクター及び関連遺伝子治療改善 |
| IL297412A (en) | 2020-05-04 | 2022-12-01 | Immunorizon Ltd | Precursor tri-specific antibody constructs and methods of use thereof |
| CN111979249B (zh) * | 2020-07-28 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一种特异性结合脂质运载蛋白-1的核酸适配体及其应用 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0388186A1 (en) * | 1989-03-17 | 1990-09-19 | E.I. Du Pont De Nemours And Company | External regulation of gene expression |
| US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5362865A (en) * | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) * | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US6818418B1 (en) * | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2002018571A2 (en) * | 2000-08-31 | 2002-03-07 | Zymogenetics, Inc. | Human phermone polypeptides |
-
2005
- 2005-03-08 GB GBGB0504767.5A patent/GB0504767D0/en not_active Ceased
-
2006
- 2006-03-08 BR BRPI0609020A patent/BRPI0609020A2/pt not_active IP Right Cessation
- 2006-03-08 US US11/817,296 patent/US20080254035A1/en not_active Abandoned
- 2006-03-08 WO PCT/GB2006/000820 patent/WO2006095164A1/en not_active Ceased
- 2006-03-08 MX MX2007010809A patent/MX2007010809A/es active IP Right Grant
- 2006-03-08 JP JP2008500259A patent/JP4933527B2/ja not_active Expired - Fee Related
- 2006-03-08 CA CA002599540A patent/CA2599540A1/en not_active Abandoned
- 2006-03-08 CN CNA2006800153195A patent/CN101189257A/zh active Pending
- 2006-03-08 AU AU2006221859A patent/AU2006221859B2/en not_active Ceased
- 2006-03-08 EP EP06710035A patent/EP1869074A1/en not_active Withdrawn
- 2006-03-08 KR KR1020077022395A patent/KR20070118614A/ko not_active Ceased
- 2006-03-08 EA EA200701918A patent/EA011816B1/ru not_active IP Right Cessation
- 2006-08-03 UA UAA200711037A patent/UA94221C2/ru unknown
-
2007
- 2007-08-27 IL IL185547A patent/IL185547A0/en unknown
- 2007-10-08 NO NO20075068A patent/NO20075068L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070118614A (ko) | 2007-12-17 |
| AU2006221859A1 (en) | 2006-09-14 |
| JP4933527B2 (ja) | 2012-05-16 |
| WO2006095164A1 (en) | 2006-09-14 |
| JP2008536483A (ja) | 2008-09-11 |
| MX2007010809A (es) | 2007-11-07 |
| UA94221C2 (en) | 2011-04-26 |
| CN101189257A (zh) | 2008-05-28 |
| EA200701918A1 (ru) | 2008-02-28 |
| EP1869074A1 (en) | 2007-12-26 |
| US20080254035A1 (en) | 2008-10-16 |
| AU2006221859B2 (en) | 2011-09-22 |
| IL185547A0 (en) | 2008-01-06 |
| NO20075068L (no) | 2007-12-10 |
| CA2599540A1 (en) | 2006-09-14 |
| EA011816B1 (ru) | 2009-06-30 |
| GB0504767D0 (en) | 2005-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004029580D1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| BRPI0416796A (pt) | compostos orgánicos | |
| Charron et al. | Neuroprotection and functional recovery conferred by administration of kappa-and delta1-opioid agonists in a rat model of global ischemia | |
| EP1302542A4 (en) | NEW, PHYSIOLOGICALLY ACTIVE PEPTIDE AND ITS USE | |
| BR0317168A (pt) | Composto ou uma forma farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de reduzir condutância de cálcio de um receptor de capsaicina celular, e de inibir ligação de ligante vanilóide a um receptor de capsaicina, métodos de tratar uma condição responsiva à modulação de receptor de capsaicina, dor, coceira, tosse ou soluços, incontinência urinária, de promover perda de peso em paciente, e de determinar a presença ou ausência de receptor de capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto | |
| BRPI0408236A (pt) | método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer | |
| EP1755598A4 (en) | METHOD FOR THE TREATMENT OF ARTHRITICAL ILLNESSES IN DOGS | |
| CR20140394A (es) | Anticuerpo monoclonal | |
| WO2005007648A3 (en) | Biaryl piperazinyl-pyridine analogues | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| WO2005007652A3 (en) | Substituted quinolin-4-ylamine analogues | |
| WO2005110982A3 (en) | Substituted 1-benzyl-4-substituted piperazine analogues | |
| WO2006026135A3 (en) | Substituted biaryl piperazinyl-pyridine analogues | |
| Dall et al. | Muscarinic receptor M4 positive allosteric modulators attenuate central effects of cocaine | |
| BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico | |
| BRPI0720236A2 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar uma infecção bacteriana em um animal de sangue quente tal como o ser humano, e, composição farmacêutica | |
| WO2005000335A3 (en) | Use of genes differentially expressed during aging of liver for treatment and diagnosis | |
| BRPI0408274A (pt) | compostos de ligação de amilóide, composição farmacêutica e método de detecção de depósito de amilóide in vivo | |
| Drysdale et al. | A peptide-containing fraction of plasma from schizophrenic patients which binds to opiate receptors and induces hyper-reactivity in rats | |
| WO2006042289A3 (en) | Substituted biaryl quinolin-4-ylamine analogues | |
| WO2010036813A8 (en) | Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation | |
| WO2004016751A3 (en) | Methods of treating neurodegenerative diseases | |
| Hannon et al. | Mycobacterium marinum infection in a blue-fronted Amazon parrot (Amazona aestiva) | |
| BRPI0412908A (pt) | composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção ou demência de alzheimer, para potenciar um efeito terapêutico de um agente do cns, para melhorar a memória de curta duração em um paciente, para alterar a atividade de transdução de sinal de receptor gabaa, e para determinar a presença ou ausência de receptor gabaa em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO 020070125634/RJ DE 06/09/2007. |
|
| B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: ANULADA A PUBLICACAO 11.6.1 NA RPI 2128 DE 18/10/2011, POR TER SIDO INDEVIDA. |
|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO 6.7 NA RPI 2066 DE 10/08/2010, POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |